Drugs / 2-AMINO-3-HYDROXY-3-(PYRIDIN-4-YL)-1-(PYRROLIDIN-1-YL)PROPAN-1-ONE, (2R,3S)-

Follow last change Apr 2025 re-read 3 minutes ago

2-AMINO-3-HYDROXY-3-(PYRIDIN-4-YL)-1-(PYRROLIDIN-1-YL)PROPAN-1-ONE, (2R,3S)-

also known as RL-007 · Inidascamine

Developed for: cognitive impairment with or without cerebellar ataxia · schizophrenia
Investigated by: Recognify Life Sciences

today NCT05686239 · Ph 2 NCT04822883 · Ph 2

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05686239	Dec 2022 → Apr 2025	cognitive impairment with or without cerebellar ataxia, schizophrenia	Recognify Life Sciences	Completed	No outcome recorded
Phase 2	NCT04822883	Apr → Oct 2021	cognitive impairment with or without cerebellar ataxia, schizophrenia	Recognify Life Sciences	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	2-AMINO-3-HYDROXY-3-(PYRIDIN-4-YL)-1-(PYRROLIDIN-1-YL)PROPAN-1-ONE, (2R,3S)-	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095258 ↗
Known as	Inidascamine	“RL-007 (Inidascamine)” NCT05686239 ↗
Known as	RL-007	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686239 ↗ 1 NCT04822883 ↗
Modality	Small molecule	— CHEMBL5095258 ↗
Route	Oral	“oral dosing three times per day (TID)” NCT05686239 ↗